- Silo Pharma (OTCQB:SILO) has entered into an agreement to license technology covered by provisional patent applications filed by Silo Pharma with the United States Patent and Trademark Office in use for patients suffering with cancer.
- The patent applications relate to using a novel peptide with Psilocybin as a therapeutic.
- This agreement is structured to provide $500k in an upfront cash payment as well as equity currently valued at $500k from a NASDAQ listed company. The Agreement also provides for Silo to collect royalties should the technology be commercialized.